Market Cap 845.70M
Revenue (ttm) 606.88M
Net Income (ttm) -225.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -37.19%
Debt to Equity Ratio 0.21
Volume 1,921,100
Avg Vol 2,420,750
Day's Range N/A - N/A
Shares Out 755.09M
Stochastic %K 17%
Beta 1.42
Analysts Sell
Price Target $2.58

Company Profile

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 305 575 4100
Address:
4400 Biscayne Boulevard, Miami, United States
tymtested
tymtested May. 13 at 12:09 AM
$OPK the market is clearly wrong about opko! It just doesn’t understand what ModeX has accomplished!
0 · Reply
Biotechguy21
Biotechguy21 May. 12 at 11:59 PM
$OPK ceo in jail????
0 · Reply
Mike18181
Mike18181 May. 12 at 10:00 PM
$OPK Since start up of 2006 , OPKO Health is now up to approximatley <2.88 Billion > dollars in Accumulated defecit. Fact : All shareholder equity is all but wiped out. Frost is not fit to run a Hotdog Cart.
0 · Reply
Mactoast
Mactoast May. 12 at 9:36 PM
$OPK Come one man. Such bullshit! I guess Frost not dropping dead must mean he has material information so he must stay alive. Either shit or get off the pot! Time for this company to move on! And calling it a conpany is being generous.
1 · Reply
Gasbagger
Gasbagger May. 12 at 8:22 PM
$OPK MDX3001 has been in the ModeX closet for over three years and it's just getting to pre-clinical????? lmao lmao ! I would love to see how much Frost and friends are charging the shareholders for the mice used in the study. I bet it's at least 10 thousand a mouse. It's called the R&D hustle. The funniest thing is, it will never work and they already know it!
0 · Reply
tymtested
tymtested May. 12 at 7:57 PM
$OPK Platform Risk: MASSIVELY De‑Risked Before today, ModeX’s in‑vivo CAR‑T platform had three major scientific risks: Can the antibody‑LNP actually target T cells in vivo? Can the mRNA actually reprogram those T cells into CAR‑T? Will those CAR‑T cells actually function systemically? Today’s data answered all three with a yes. This is a huge de‑risking event. It moves the platform from “theoretical” → “validated in animals.” This is the single biggest scientific de‑risking OPKO has had since ModeX was acquired.
0 · Reply
tymtested
tymtested May. 12 at 5:57 PM
$OPK the absence of insider buying is likely BULLISH, indicating the probability of sitting on material nonpublic information.
0 · Reply
Gasbagger
Gasbagger May. 12 at 5:37 PM
$OPK 111 pennies says ModeX is nothing more than a High School Chemistry project to siphon all the cash out through R&D. 111 pennies tells you the Scientific Community thinks the same exact thing.
0 · Reply
tymtested
tymtested May. 12 at 5:28 PM
$OPK HUGE AWESOME AMAZING BUYING OPPORTUNITY!! In‑vivo CAR‑T with systemic B‑cell depletion is a multi‑billion‑dollar platform breakthrough. BIG PHARMA IS CHASING THE SAME THING!!
0 · Reply
tymtested
tymtested May. 12 at 5:10 PM
$OPK These diseases need B‑cell depletion because B cells are the problem: 1. B‑cell cancers (the big one) Non‑Hodgkin lymphoma CLL Mantle cell lymphoma DLBCL Multiple myeloma precursors (some contexts) In these diseases, malignant B cells are the target. Depleting them = therapeutic success. This is why CD19 CAR‑T works — it wipes out CD19+ B cells systemically.
0 · Reply
Latest News on OPK
OPKO Health Earnings Call Transcript: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 14 days ago

OPKO Health Earnings Call Transcript: Q1 2026


OPKO Health Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 2 months ago

OPKO Health Earnings Call Transcript: Q4 2025


Opko Health initiated with a Neutral at JPMorgan

2025-11-20T09:50:09.000Z - 6 months ago

Opko Health initiated with a Neutral at JPMorgan


Opko Health downgraded to Hold from Buy at Jefferies

2025-10-30T20:10:16.000Z - 6 months ago

Opko Health downgraded to Hold from Buy at Jefferies


Opko Health reports Q3 EPS 3c, consensus (5c)

2025-10-29T20:36:22.000Z - 6 months ago

Opko Health reports Q3 EPS 3c, consensus (5c)


OPKO Health Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 6 months ago

OPKO Health Earnings Call Transcript: Q3 2025


Opko Health’s ModeX Therapeutics begins trial of MDX2004

2025-10-28T12:21:29.000Z - 7 months ago

Opko Health’s ModeX Therapeutics begins trial of MDX2004


Opko Health management to meet with Barrington

2025-09-22T12:00:42.000Z - 8 months ago

Opko Health management to meet with Barrington


OPKO Health Earnings Call Transcript: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 10 months ago

OPKO Health Earnings Call Transcript: Q2 2025


NextPlat Issues Interim CEO Update Shareholder Letter

Jun 30, 2025, 8:01 AM EDT - 11 months ago

NextPlat Issues Interim CEO Update Shareholder Letter

NXPL


Opko Health’s ModeX forms Scientific Advisory Board

2025-06-09T12:21:02.000Z - 1 year ago

Opko Health’s ModeX forms Scientific Advisory Board


OPKO Health Earnings Call Transcript: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings Call Transcript: Q1 2025


Opko Health initiated with a Neutral at JPMorgan

2025-04-25T09:15:19.000Z - 1 year ago

Opko Health initiated with a Neutral at JPMorgan


Opko Health management to meet with Piper Sandler

2025-03-25T18:57:10.000Z - 1 year ago

Opko Health management to meet with Piper Sandler


Opko Health CEO buys $348K in common stock

2025-03-17T21:50:06.000Z - 1 year ago

Opko Health CEO buys $348K in common stock


OPKO and Entera partner to develop obesity pill

Mar 17, 2025, 8:57 AM EDT - 1 year ago

OPKO and Entera partner to develop obesity pill


OPKO Health Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Earnings Call Transcript: Q4 2024


OPKO Health Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Earnings Call Transcript: Q3 2024


OPKO Health Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

OPKO Health Earnings Call Transcript: Q2 2024


OPKO Health Earnings Call Transcript: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings Call Transcript: Q1 2024


OPKO Health Earnings Call Transcript: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Earnings Call Transcript: Q4 2023


OPKO Health Earnings Call Transcript: Q3 2023

Nov 6, 2023, 4:30 PM EST - 2 years ago

OPKO Health Earnings Call Transcript: Q3 2023


OPKO Health Earnings Call Transcript: Q2 2023

Aug 3, 2023, 4:30 PM EDT - 3 years ago

OPKO Health Earnings Call Transcript: Q2 2023


tymtested
tymtested May. 13 at 12:09 AM
$OPK the market is clearly wrong about opko! It just doesn’t understand what ModeX has accomplished!
0 · Reply
Biotechguy21
Biotechguy21 May. 12 at 11:59 PM
$OPK ceo in jail????
0 · Reply
Mike18181
Mike18181 May. 12 at 10:00 PM
$OPK Since start up of 2006 , OPKO Health is now up to approximatley <2.88 Billion > dollars in Accumulated defecit. Fact : All shareholder equity is all but wiped out. Frost is not fit to run a Hotdog Cart.
0 · Reply
Mactoast
Mactoast May. 12 at 9:36 PM
$OPK Come one man. Such bullshit! I guess Frost not dropping dead must mean he has material information so he must stay alive. Either shit or get off the pot! Time for this company to move on! And calling it a conpany is being generous.
1 · Reply
Gasbagger
Gasbagger May. 12 at 8:22 PM
$OPK MDX3001 has been in the ModeX closet for over three years and it's just getting to pre-clinical????? lmao lmao ! I would love to see how much Frost and friends are charging the shareholders for the mice used in the study. I bet it's at least 10 thousand a mouse. It's called the R&D hustle. The funniest thing is, it will never work and they already know it!
0 · Reply
tymtested
tymtested May. 12 at 7:57 PM
$OPK Platform Risk: MASSIVELY De‑Risked Before today, ModeX’s in‑vivo CAR‑T platform had three major scientific risks: Can the antibody‑LNP actually target T cells in vivo? Can the mRNA actually reprogram those T cells into CAR‑T? Will those CAR‑T cells actually function systemically? Today’s data answered all three with a yes. This is a huge de‑risking event. It moves the platform from “theoretical” → “validated in animals.” This is the single biggest scientific de‑risking OPKO has had since ModeX was acquired.
0 · Reply
tymtested
tymtested May. 12 at 5:57 PM
$OPK the absence of insider buying is likely BULLISH, indicating the probability of sitting on material nonpublic information.
0 · Reply
Gasbagger
Gasbagger May. 12 at 5:37 PM
$OPK 111 pennies says ModeX is nothing more than a High School Chemistry project to siphon all the cash out through R&D. 111 pennies tells you the Scientific Community thinks the same exact thing.
0 · Reply
tymtested
tymtested May. 12 at 5:28 PM
$OPK HUGE AWESOME AMAZING BUYING OPPORTUNITY!! In‑vivo CAR‑T with systemic B‑cell depletion is a multi‑billion‑dollar platform breakthrough. BIG PHARMA IS CHASING THE SAME THING!!
0 · Reply
tymtested
tymtested May. 12 at 5:10 PM
$OPK These diseases need B‑cell depletion because B cells are the problem: 1. B‑cell cancers (the big one) Non‑Hodgkin lymphoma CLL Mantle cell lymphoma DLBCL Multiple myeloma precursors (some contexts) In these diseases, malignant B cells are the target. Depleting them = therapeutic success. This is why CD19 CAR‑T works — it wipes out CD19+ B cells systemically.
0 · Reply
tymtested
tymtested May. 12 at 5:04 PM
$OPK Its essentially saying how CAR-T cells are engineered in the body to destroy the problems(B-cells) and its proven effective in animal models and nonhuman primates!!! GO MODEX GO OPKO!! B-cells are the problem in autoimmune diseases.
0 · Reply
tymtested
tymtested May. 12 at 5:00 PM
$OPK today's announcement is AWESOME! Why it’s AWESOME! “Multispecific antibody‑conjugated LNP/mRNA platform” Accurately describes the CD3×CD28‑targeted LNPs carrying mRNA. “Enables in vivo T‑cell engineering” This is the core breakthrough — generating CAR‑T cells inside the body. “Systemic B‑cell depletion” Matches the reported depletion in blood, spleen, lymph nodes, and bone marrow. “In animal models” Correctly scopes the claim to preclinical data (mice + NHPs).
0 · Reply
tymtested
tymtested May. 12 at 12:13 PM
$OPK https://www.opko.com/investors/news-events/press-releases/detail/546/opko-healths-modex-therapeutics-will-present-data-demonstrating-in-vivo-car-t-cell-generation-and-deep-b-cell-depletion-in-preclinical-studies
0 · Reply
Mike18181
Mike18181 May. 12 at 1:23 AM
$OPK Ok Bud Fox ! Buy me 100 shares of Sominex ,Health. Inc symbol (OPK) and dont screw this up !
0 · Reply
tradertrash
tradertrash May. 12 at 12:55 AM
$OPK worry about the stock...WHY? make a killing for years by not giving a sh*t about it, look at a chart, look at raises and bonuses thru the years, no one has been laid off or fired for years of horrendous stock performance, ITS THE R&D GRAVY TRAIN BABY!
0 · Reply
tradertrash
tradertrash May. 12 at 12:49 AM
$OPK frosty has had years to train the commodeX cowboys, i see nothing but a continuation of the same into the future, he laid the blue print, all they have to do is follow it, it's my thought they will, they have been comfortable getting paid, very well, for failure for years, as a long term investor i don't see anything that would make me think this won't continue, failure has just been too lucrative for them, my thoughts my honest opinion
0 · Reply
MyMoneyMyOpinion
MyMoneyMyOpinion May. 11 at 10:23 PM
$OPK the minute frost dies this is going to quadruple in 10 minutes. 400% im just waiting ✋️
0 · Reply
Gasbagger
Gasbagger May. 11 at 6:13 PM
$OPK something doesnt smell right with the ModeX Lab lease. The lease is 325 THOUSAND a month. but yet ModeX hasnt produced anything NEW in over 2 years. It just doesn't make any sense. Its called the R&D hustle.
1 · Reply
Gasbagger
Gasbagger May. 11 at 4:44 PM
$OPK all the $$$$$$$ is slowly disappearing with nothing to show for it. Frost doesnt care about the stock price. He has even said that.
0 · Reply
tradertrash
tradertrash May. 11 at 2:10 PM
$OPK commodeX is just a money pit imo, salaries and rent for no return for sh
0 · Reply
tradertrash
tradertrash May. 11 at 2:01 PM
$OPK like to see them pharm-out commodeX, cut out the salaries and rent, stop spending more than they make, getting rid of commodeX would be a great first step,
0 · Reply
tradertrash
tradertrash May. 11 at 1:57 PM
$OPK Failure is very Lucrative
0 · Reply